The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical ( BMRN ) announced that the U.S. FDA has approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene ther...